Sign up
Pharma Capital

ImmuPharma says managed access programme for Lupozor progressing as planned

The AIM-listed firm said that following analysis of the regulatory processes in EU countries, it is planned to begin patient recruitment for the programme in France and UK
Biopharma
ImmuPharma chairman Tim McCarthy also said that active discussions regarding the appointment of a new NOMAD are ongoing

ImmuPharma PLC (LON:IMM) shares rose on Friday as the biopharma firm revealed that the managed access programme (MAP) for Lupozor, its late-stage treatment for auto-immune disease Lupus is progressing as planned.

In an update on corporate activities, the AIM-listed firm said that following analysis of the regulatory processes in EU countries, it is planned to begin patient recruitment for the programme in France and UK and then roll out to other EU countries.

WATCH: ImmuPharma firmly committed to Lupuzor ahead of managed access programme

Tim McCarthy, ImmuPharma’s chairman, said: "We are delighted to be progressing the necessary activities for the Managed Access Programme, allowing Lupus patients early access to Lupuzor.

 “In conjunction, in the medium term we remain focused on achieving the full regulatory approval of Lupuzor, which we are confident has the potential to be a ground-breaking drug for Lupus patients.”

The company also said that, further to the ‘Heads of Terms’ agreement announced on 7 September 2018 regarding a clinical development collaboration for its Nucant cancer programme with specialist oncology development company, Incanthera Limited, the two companies are making good progress in finalising the 'Definitive Licence Agreement' within the exclusivity period up to 31 December 2018.

Ureka evaluation process

ImmuPharma also stated in its announcement of 7 September that it would commence a process of considering all opportunities to divest its Ureka business, and said today that, following this period of review, the firm intends to engage the services of a leading specialist R&D and advisory firm in the sector, to support the evaluation of Ureka's technologies and drug candidates and the development activities for the progression of its assets and the business.

It added: “This process is ongoing and further updates will be announced as appropriate.”

McCarthy commented: "Our Nucant programme and Ureka subsidiary continue to progress with their separate strategies, both having the ultimate goal of achieving value for all stakeholders going forward.”

McCarthy also said that active discussions regarding the appointment of a new NOMAD are ongoing and added: “We look forward to updating the market and shareholders again in the near future."

In early morning trading, ImmuPharma shares were 6% higher at 13p.

View full IMM profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.